Attendance an online digital event on July. 16, 2024 entitled “Advancements in Inhalable Nano-Drug Delivery Systems for Targeted Lung Therapy”. The event was offered by International Pharmaceutical Federation (FIP).

Description: Inhalable treatments supply a unique benefit by offering both localized, targeted therapy and systemic treatment. Despite the several advantages of inhalable medication administration, current therapy for pulmonary disorders oftentimes depends on other delivery routes, leading to off-target toxicities and suboptimal therapeutic effects. This preference is affected, in part, through the existence of protection mechanisms in the lungs which are actively participated in clearing foreign materials containing medications entering the lungs. However, inhalable nanoparticle-based medication delivery carriers, at what time optimized, have presented promise in delivering treatments in a sustained and targeted way to the profound lung tissue for the therapy of many lung disorders containing fibrosis, inflammation and cancer. The present webinar explored present strategies in the improvement and surface modulation of inhalable nanoparticles to deliver treatments successfully to the lungs and overcome obstacles. In particular, the panelist discussed modern efforts in improving lipid- and polymer-based nanoparticles designed to avoid macrophage realization and uptake in the lungs.

Moderator:

- Mathew Cherian PhD, VP of Operations & Development ReVive Biotechnology, United States.

- Nikolina Biskic, Manager Regulatory Affairs, Switzerland.

Panellist:

- Jyothi Menon PhD, Associate Professor, Biomedical, Pharmaceutical Sciences and Chemical Engineering University of Rhode Island, USA.